Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

864 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?
Fanale D, Corsini LR, Brando C, Cutaia S, Di Donna MC, Filorizzo C, Lisanti MC, Randazzo U, Magrin L, Romano R, Bazan Russo TD, Olive D, Vieni S, Pantuso G, Chiantera V, Russo A, Bazan V, Iovanna JL. Fanale D, et al. Among authors: olive d. Front Oncol. 2022 Sep 21;12:946319. doi: 10.3389/fonc.2022.946319. eCollection 2022. Front Oncol. 2022. PMID: 36212445 Free PMC article.
BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC).
Benyamine A, Loncle C, Foucher E, Blazquez JL, Castanier C, Chrétien AS, Modesti M, Secq V, Chouaib S, Gironella M, Vila-Navarro E, Montalto G, Dagorn JC, Dusetti N, Iovanna J, Olive D. Benyamine A, et al. Among authors: olive d. Oncoimmunology. 2017 Sep 21;7(1):e1372080. doi: 10.1080/2162402X.2017.1372080. eCollection 2017. Oncoimmunology. 2017. PMID: 29296524 Free PMC article.
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?
Incorvaia L, Badalamenti G, Rinaldi G, Iovanna JL, Olive D, Swayden M, Terruso L, Vincenzi B, Fulfaro F, Bazan V, Russo A, Fanale D. Incorvaia L, et al. Among authors: olive d. Ther Adv Med Oncol. 2019 May 13;11:1758835919848872. doi: 10.1177/1758835919848872. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31205506 Free PMC article.
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
Incorvaia L, Fanale D, Badalamenti G, Porta C, Olive D, De Luca I, Brando C, Rizzo M, Messina C, Rediti M, Russo A, Bazan V, Iovanna JL. Incorvaia L, et al. Among authors: olive d. Oncoimmunology. 2020 Oct 27;9(1):1832348. doi: 10.1080/2162402X.2020.1832348. Oncoimmunology. 2020. PMID: 33178494 Free PMC article.
BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM.
Battin C, Leitner J, Waidhofer-Söllner P, Grabmeier-Pfistershammer K, Olive D, Steinberger P. Battin C, et al. Among authors: olive d. Front Immunol. 2022 Aug 23;13:956694. doi: 10.3389/fimmu.2022.956694. eCollection 2022. Front Immunol. 2022. PMID: 36081508 Free PMC article.
864 results